Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study
Elevated PIV levels predict adverse survival outcomes and progression in UCB, underscoring its potential as a cost-effective and accessible biomarker for risk stratification. Prospective validation in larger cohorts is warranted to confirm its role in personalized patient management.
Authors
- Mustafa Yıldız (ORCID: https://orcid.org/0000-0001-7832-5989)
- Ekrem İslamoğlu (ORCID: https://orcid.org/0000-0003-0693-0666)
- Arda Durak
- Ali Erhan Eren (ORCID: https://orcid.org/0000-0002-4675-4604)
- Eren Erdi Aksaray (ORCID: https://orcid.org/0000-0003-1074-1016)
- Asım Armağan Aydın (ORCID: https://orcid.org/0000-0001-8749-9825)
- Ahmet Ünlü (ORCID: https://orcid.org/0000-0001-6654-3815)
- Banu Öztürk (ORCID: https://orcid.org/0000-0003-0290-8787)
Institutions
- Antalya Bilim University (TR)
- Antalya Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Antalya IVF (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.3390/curroncol32100534
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00